IGA NEPHROPATHY (IGAN)

Clinical trials for IGA NEPHROPATHY (IGAN) explained in plain language.

Never miss a new study

Get alerted when new IGA NEPHROPATHY (IGAN) trials appear

Sign up with your email to follow new studies for IGA NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 4 Not yet finished but already full! 1

New injection aims to slow kidney damage in IgA patients

Disease control Recruiting now

This study tests an experimental drug called RG002C0106 in 30 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants receive either the drug or a placebo, and neither they nor their doctors know which. The goal is to see if the drug safely red…

Matched conditions: IGA NEPHROPATHY (IGAN)

Phase: PHASE2 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Disease control

Last updated Apr 30, 2026 15:50 UTC

IGA NEPHROPATHY (IGAN)

Get alerted when new IGA NEPHROPATHY (IGAN) trials appear

New injection aims to slow kidney damage in IgA patients